Skip to main content
Article thumbnail
Location of Repository

Efficient generation of A9 midbrain dopaminergic neurons by lentiviral delivery of LMX1A in human embryonic stem cells and Induced Pluripotent Stem Cells

By Adriana Sánchez-Danés, Antonella Consiglio, Y. Richaud, I. Rodriguez-Piza, B. Dehay, Michael John Edel, J. Bove, M. Memo, M. Vila, Ángel Raya Chamorro and Juan Carlos Izpisúa Belmonte

Abstract

Human embryonic stem cells (hESC) and induced pluripotent stem cells (iPSC) offer great hope for in vitro modeling of Parkinson's disease (PD), as well as for designing cell-replacement therapies. To realize these opportunities, there is an urgent need to develop efficient protocols for the directed differentiation of hESC/iPSC into dopamine (DA) neurons with the specific characteristics of the cell population lost to PD, i.e., A9-subtype ventral midbrain DA neurons. Here we use lentiviral vectors to drive the expression of LMX1A, which encodes a transcription factor critical for ventral midbrain identity, specifically in neural progenitor cells. We show that clonal lines of hESC engineered to contain one or two copies of this lentiviral vector retain long-term self-renewing ability and pluripotent differentiation capacity. Greater than 60% of all neurons generated from LMX1A-engineered hESC were ventral midbrain DA neurons of the A9 subtype, compared with ∼10% in green fluorescent protein <br>engineered controls, as judged by specific marker expression and functional analyses. Moreover, DA neuron precursors differentiated from LMX1A-engineered hESC were able to survive and differentiate when grafted into the brain of adult mice. Finally, we provide evidence that LMX1A overexpression similarly increases the yield of DA neuron differentiation from human iPSC. Taken together, our data show that stable genetic engineering of hESC/iPSC with lentiviral vectors driving controlled expression of LMX1A is an efficient way to generate enriched populations of human A9-subtype ventral midbrain DA neurons, which should prove useful for modeling PD and may be helpful for designing future cell-replacement strategies

Topics: Cèl·lules mare, Malaltia de Parkinson, Teràpia genètica, Enginyeria genètica, Stem cells, Parkinson's disease, Gene therapy, Genetic engineering
Publisher: Mary Ann Liebert, Inc.
Year: 2015
DOI identifier: 10.1089/hum.2011.054
OAI identifier: oai:diposit.ub.edu:2445/66244
Journal:

Suggested articles


To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.